Featured Articles

  1. What The ICH Q5A Virus Safety Guidelines Mean For Your Cell & Gene Therapy Product 2/19/2025

    Explore Cell & Gene therapy (CGT) products now within scope of the ICH Q5A guidance, technologies that can replace traditional testing strategies, viral clearance studies expected for vector products, and more.

  2. Purity As A Priority: Optimizing Safety Measures For rAAV Therapies 2/11/2025

    Watch to learn how rAAV vectors in gene therapy are addressing manufacturing impurities, risks to patient safety, and analytical methods for detection while aiding sponsors in regulatory compliance.

  3. Limiting Off-Target Effects Of CRISPR-Based Products 2/11/2025

    Find out how to enhance CRISPR gene editing specificity by using Next Generation Sequencing to improve sgRNA quality control, addressing off-target effects and ensuring higher sequence fidelity.

  4. Applying Next Generation Sequencing To Accelerate CGT Product Development 2/11/2025

    Next Generation Sequencing (NGS) revolutionizes gene therapy by enhancing the development and safety of viral vectors like AAV and lentivirus. Discover more about its impact.

  5. Adapting A Hybrid Analysis For AAV Characterization 2/11/2025

    Gain insights into utilizing hybrid long-read and short-read sequencing to analyze adeno-associated virus capsids to enhance biosafety testing and genome assembly while achieving high identity mapping.

  6. Building Local Biomanufacturing Capacity In South Africa 2/11/2025

    Biovac evolved from a vaccine supplier to a biopharmaceutical innovator, providing a blueprint for expanding Africa's vaccine manufacturing capacity. Gain valuable insights from their journey.

  7. Bridging Clinical And Commercial Needs 1/29/2025

    Discover how viral vector CDMO services can provide a solution to streamline gene therapy development, balancing clinical and commercial needs, to reduce delays and costs.

  8. How To Prevent Protein Aggregation Through Stabilizers And Surfactants 1/13/2025

    Learn about protein aggregation mechanisms, the role of excipients in stabilization, and novel surfactants that prevent aggregation in therapeutic protein formulations in this webinar.

  9. Optimizing Poloxamer 188 1/13/2025

    Poloxamer 188 stabilizes proteins in liquid formulations and protects cells from shear stress. Molecular weight and hydrophobicity variations influence its effectiveness in different biopharmaceutical applications.

  10. Emerge Logistical Solutions 12/23/2024

    Explore how the eMERGE™ program digitizes the biopharma supply chain, streamlining raw material receipt, and enhancing efficiency with advanced shipping notifications and integrated systems.